ATE419247T1 - Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk) - Google Patents
Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk)Info
- Publication number
- ATE419247T1 ATE419247T1 AT02767208T AT02767208T ATE419247T1 AT E419247 T1 ATE419247 T1 AT E419247T1 AT 02767208 T AT02767208 T AT 02767208T AT 02767208 T AT02767208 T AT 02767208T AT E419247 T1 ATE419247 T1 AT E419247T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonamide derivatives
- group
- jnk
- inhibitors
- jun
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 abstract 5
- 150000003456 sulfonamides Chemical class 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 abstract 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01116798 | 2001-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE419247T1 true ATE419247T1 (de) | 2009-01-15 |
Family
ID=8177999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02767208T ATE419247T1 (de) | 2001-07-23 | 2002-07-15 | Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk) |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7683078B2 (de) |
| EP (1) | EP1409483B1 (de) |
| JP (1) | JP4414219B2 (de) |
| AT (1) | ATE419247T1 (de) |
| AU (1) | AU2002331253B2 (de) |
| CA (1) | CA2452259A1 (de) |
| DE (1) | DE60230625D1 (de) |
| ES (1) | ES2318041T3 (de) |
| IL (1) | IL159767A0 (de) |
| WO (1) | WO2003010164A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE551997T1 (de) * | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
| WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
| EP1676574A3 (de) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| US9889089B2 (en) * | 2016-04-04 | 2018-02-13 | Golden Products Llc | Dietary supplement non-fluoride toothpaste and methods of making and using same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3812144A (en) * | 1969-03-10 | 1974-05-21 | Ciba Geigy Corp | Derivatives of p-aminoalkylbenzene sulfonamide |
| US5744320A (en) * | 1995-06-07 | 1998-04-28 | Promega Corporation | Quenching reagents and assays for enzyme-mediated luminescence |
| DK1149092T3 (da) | 1998-12-17 | 2004-02-23 | Hoffmann La Roche | 4- og 5-alkynyloxindoler og 4- og 5-alkenyloxindoler |
| BR9916223A (pt) | 1998-12-17 | 2001-09-04 | Hoffmann La Roche | 4-ariloxindóis como inibidores de cinases de proteìna jnk |
| CA2354402A1 (en) | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4,5-pyrazinoxindoles as protein kinase inhibitors |
| ATE425142T1 (de) | 1999-04-23 | 2009-03-15 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
| AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| JP2003531103A (ja) | 1999-08-12 | 2003-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤 |
| WO2001012609A1 (en) | 1999-08-19 | 2001-02-22 | Signal Pharmaceuticals, Inc. | Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| CA2318004A1 (en) | 1999-09-15 | 2001-03-15 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
| EP1088821A1 (de) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksamer Sulfonamid Derivate |
| EP1088822A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksame Sulfonyl Hydrazid-Derivate |
| EP1088815A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate |
| EP1110957A1 (de) | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazolderivate und ihre Verwendung als JNK Modulatoren |
| HUP0400494A3 (en) | 2000-03-24 | 2004-08-30 | Mediquest Therapeutics Inc Sea | Polyamine analogues as cytotoxic agents and pharmaceutical compositions containing them |
| EP1193268A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen |
| EP1193256A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch aktive Benzolsulfonamidderivate als JNK-Proteininhibitoren |
| EP1193267A1 (de) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksame hydrophile Sulfonamidderivate zur Verwendung als Proteinjunkinasehemmer |
| ATE551997T1 (de) * | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
| WO2007141224A2 (en) * | 2006-06-02 | 2007-12-13 | Laboratoires Serono Sa | Jnk inhibitors for treatment of skin diseases |
-
2002
- 2002-07-15 AT AT02767208T patent/ATE419247T1/de not_active IP Right Cessation
- 2002-07-15 JP JP2003515523A patent/JP4414219B2/ja not_active Expired - Fee Related
- 2002-07-15 IL IL15976702A patent/IL159767A0/xx unknown
- 2002-07-15 EP EP02767208A patent/EP1409483B1/de not_active Expired - Lifetime
- 2002-07-15 WO PCT/EP2002/007832 patent/WO2003010164A1/en not_active Ceased
- 2002-07-15 US US10/484,744 patent/US7683078B2/en not_active Expired - Fee Related
- 2002-07-15 AU AU2002331253A patent/AU2002331253B2/en not_active Ceased
- 2002-07-15 ES ES02767208T patent/ES2318041T3/es not_active Expired - Lifetime
- 2002-07-15 CA CA002452259A patent/CA2452259A1/en not_active Abandoned
- 2002-07-15 DE DE60230625T patent/DE60230625D1/de not_active Expired - Lifetime
-
2009
- 2009-09-24 US US12/565,988 patent/US20100029719A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1409483A1 (de) | 2004-04-21 |
| US7683078B2 (en) | 2010-03-23 |
| WO2003010164A1 (en) | 2003-02-06 |
| CA2452259A1 (en) | 2003-02-06 |
| US20100029719A1 (en) | 2010-02-04 |
| JP2005504031A (ja) | 2005-02-10 |
| EP1409483B1 (de) | 2008-12-31 |
| DE60230625D1 (de) | 2009-02-12 |
| ES2318041T3 (es) | 2009-05-01 |
| JP4414219B2 (ja) | 2010-02-10 |
| AU2002331253B2 (en) | 2008-04-03 |
| US20040248886A1 (en) | 2004-12-09 |
| IL159767A0 (en) | 2004-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| NO20053645L (no) | (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| HUP0303538A2 (hu) | Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények | |
| TNSN03110A1 (en) | Azaindoles. | |
| IS7965A (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| DE602004007239D1 (de) | 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN | |
| HUP0203965A2 (en) | Indazole compounds and pharmaceutical compositions containing them | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| HUP0202490A2 (hu) | Indazolszármazékok és ezeket tartalmazó protein-kináz gátló hatású gyógyszerkészítmények | |
| DE602004022668D1 (de) | 5-gliedrige heterocyclische p-38 inhibitoren | |
| SE0402735D0 (sv) | Novel compounds | |
| MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
| TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
| ATE364605T1 (de) | 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität | |
| DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
| MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |